Second Sight Medical Products Inc. closed up more than 27 percent Wednesday after announcing the results of a two-year study of its Orion visual prosthesis.

Shares of Sylmar-based Second Sight (EYES) closed up $1.38, or 27.6 percent, to $6.38 on the Nasdaq, on a day when that market closed down nearly 2.7 percent.


In the study, five out of five patients tested at the two-year mark were able to locate a white square on a dark computer screen significantly better using the Orion System than without it. Additionally, four out of the five were able to better identify the direction of motion of a bar moving across a computer screen with the Orion System on, the company said.


Conducted at UCLA and Baylor College of Medicine, the study was paused due to the coronavirus pandemic but has since resumed at both medical centers.


“We are excited to resume the study and see such promising results, especially after all visits were paused for several months due to COVID-19,” Jessy Dorn, vice president of clinical and scientific research at Second Sight, said in a statement.